{
  "id": 1606053,
  "title": "Earnings call transcript: CSL shares jump 16.4% after FY 2026 reset year",
  "url": "https://urgent.news/2026/08/18/earnings-call-transcript-csl-shares-jump-16-4-after-fy-2026-reset-year",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T01:27:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-csl-shares-jump-164-after-fy-2026-reset-year-93CH-4864174"
  },
  "original_language": "en",
  "account": "CSL Limited reported FY 2026 as a \"reset year\" for its Australian biotech and plasma specialist. Despite a 1% decline in revenue to $15.8 billion on a constant-currency basis, investors focused on signs of growth, strong cash flow, and a larger buyback. Underlying NPAT-A fell 2% to $3.1 billion, while statutory net profit turned into a $2.6 billion loss due to $6.0 billion in post-tax restructuring and impairment charges. The stock surged 16.4% to $156.68, highlighting investors' focus on the company's forward outlook, cost savings, and capital returns. Despite the statutory loss, CSL remained profitable on an underlying basis, with operating cash flow reaching $3.5 billion. CSL is guided to about 5% NPAT growth in FY 2027, with CSL Behring expected to deliver mid-single-digit revenue growth and Vifor facing a 25% revenue decline. Seqirus is forecast to post low-single-digit revenue growth, driven by new markets and the first season of Algemflu in the U.K.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Judo Bank H2 2026 profit jumps as shares rise 9%",
        "url": "https://urgent.news/2026/08/18/earnings-call-transcript-judo-bank-h2-2026-profit-jumps-as-shares",
        "published": "2026-08-18T01:33:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}